In an era characterized by macro headwinds and profound market volatility, the biotech industry continues to raise capital to fuel drug development, clinical trials, and innovation. Capital raising in challenging markets comes with additional risks, leading venture capital firms and crossover investors to identify creative, unconventional deal structures and strategies that are redefining the biotech investment landscape.

Join Chen Yu, Founder & Managing Partner at TCGX, Matthew Young, Managing Director at Longitude Capital, Arsani William, CIO & Managing Partner at Logos Capital, and RBC’s Noël Brown, Head of US Biotechnology Investment Banking, for a roundtable discussion exploring how investors across the biotech ecosystem are navigating market complexity to put dollars to work creatively to manage risks, maximize rewards, and stimulate growth.